Zhuo Ying, Song Yan
Pulmonary Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Environ Toxicol. 2025 Mar;40(3):396-411. doi: 10.1002/tox.24185. Epub 2024 Mar 6.
Lung adenocarcinoma (LUAD) poses significant clinical challenges due to its inherent heterogeneity and variable response to treatment. Recent research has specifically focused on elucidating the role of Paraptosis-related genes (PRGs) in the progression of cancer and the prognosis of patients.
We conducted a comprehensive analysis of the differential expression of PRGs in LUAD. Additionally, univariate Cox regression analysis was utilized to determine the prognostic significance of these genes. Furthermore, consensus clustering was employed to differentiate molecular subtypes within LUAD, while immune heterogeneity was assessed. To evaluate treatment outcomes, the expression of immune checkpoint inhibitors was examined, and the sensitivity of LUAD patients to chemotherapy drugs was assessed. Moreover, machine learning algorithms were employed to construct a Paraptosis-related risk score with prognostic and immunological indicators. Finally, to validate the findings, in vitro experiments were performed to verify the regulatory effect of key PRGs on Paraptosis.
Our analysis identified 24 PRGs that exhibited differential expression, with CDKN3, TP53, and PHB emerging as the most prominently upregulated genes in tumor tissues. Among these genes, seven were identified as prognostic markers, with HSPB8 being the sole protective factor. Notably, our analysis also revealed the existence of two distinct molecular subtypes within LUAD, each characterized by unique prognoses and immune responses. Specifically, Subtype B displayed a poorer prognosis but demonstrated increased sensitivity to both chemotherapy and immunotherapy. In addition, our development of a Paraptosis-Associated Risk Score yielded a significant prognostic value in predicting patient outcomes. Furthermore, we found regulatory effect of CDKN3 on Paraptosis in two cell lines.
Our study highlights the importance of PRGs in LUAD, particularly in prognosis and treatment response. The identified molecular subtypes and Paraptosis-Associated Risk Score offer valuable insights for personalized treatment strategies.
肺腺癌(LUAD)因其固有的异质性和对治疗的可变反应而带来重大临床挑战。最近的研究特别关注阐明细胞凋亡相关基因(PRGs)在癌症进展和患者预后中的作用。
我们对LUAD中PRGs的差异表达进行了全面分析。此外,采用单变量Cox回归分析来确定这些基因的预后意义。此外,运用共识聚类来区分LUAD内的分子亚型,同时评估免疫异质性。为了评估治疗结果,检测了免疫检查点抑制剂的表达,并评估了LUAD患者对化疗药物的敏感性。此外,采用机器学习算法构建具有预后和免疫指标的细胞凋亡相关风险评分。最后,为了验证研究结果,进行了体外实验以验证关键PRGs对细胞凋亡的调节作用。
我们的分析确定了24个表现出差异表达的PRGs,其中CDKN3、TP53和PHB是肿瘤组织中上调最显著的基因。在这些基因中,有7个被确定为预后标志物,其中HSPB8是唯一的保护因子。值得注意的是,我们的分析还揭示了LUAD内存在两种不同的分子亚型,每种亚型都具有独特的预后和免疫反应特征。具体而言,B亚型预后较差,但对化疗和免疫治疗均表现出更高的敏感性。此外,我们开发的细胞凋亡相关风险评分在预测患者预后方面具有显著的预后价值。此外,我们发现CDKN3在两种细胞系中对细胞凋亡具有调节作用。
我们的研究强调了PRGs在LUAD中的重要性,特别是在预后和治疗反应方面。所确定的分子亚型和细胞凋亡相关风险评分为个性化治疗策略提供了有价值的见解。